Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases
CONCLUSION: There was no evidence for a difference between the two groups in terms of discontinuation rates, efficacy, and safety. To provide further evidence, future studies using more precise dose-escalation protocols are warranted.PMID:38563202 | DOI:10.1080/03009742.2024.2327159 (Source: Scandinavian Journal of Rheumatology)
Source: Scandinavian Journal of Rheumatology - April 2, 2024 Category: Rheumatology Authors: M Ayano K Tsubouchi K Suzuki Y Kimoto Y Arinobu K Akashi T Horiuchi I Okamoto H Niiro Source Type: research
Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases
CONCLUSION: There was no evidence for a difference between the two groups in terms of discontinuation rates, efficacy, and safety. To provide further evidence, future studies using more precise dose-escalation protocols are warranted.PMID:38563202 | DOI:10.1080/03009742.2024.2327159 (Source: Scandinavian Journal of Rheumatology)
Source: Scandinavian Journal of Rheumatology - April 2, 2024 Category: Rheumatology Authors: M Ayano K Tsubouchi K Suzuki Y Kimoto Y Arinobu K Akashi T Horiuchi I Okamoto H Niiro Source Type: research
Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease
AbstractAnti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis (anti-MDA5-DM) is frequently complicated by progressive interstitial lung disease (ILD), the prognosis of which is poor, and management is a major challenge. We treated three patients with anti-MDA5-DM-associated ILD (anti-MDA5-DM-ILD) using the Janus kinase (JAK) inhibitor, baricitinib, which improved lung opacities and saved two patients. We reviewed 6 patients with anti-MDA5-DM-ILD who had been treated with tofacitinib at our institution. Five of the patients survived, although discontinuation of tofacitinib due to complications...
Source: Rheumatology International - April 2, 2024 Category: Rheumatology Source Type: research
NR2F2 alleviates pulmonary fibrosis by inhibition of epithelial cell senescence
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal, and aging-associated interstitial lung disease with a poor prognosis and limited treatment options, while the pathogenesis remains elusive.... (Source: Respiratory Research)
Source: Respiratory Research - April 2, 2024 Category: Respiratory Medicine Authors: Ruyan Wan, Siqi Long, Shuaichen Ma, Peishuo Yan, Zhongzheng Li, Kai Xu, Hui Lian, Wenwen Li, Yudi Duan, Miaomiao Zhu, Lan Wang and Guoying Yu Tags: Research Source Type: research
Successful treatment with tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature
We describe two female Japanese patients with anti-MDA5 Ab + JDM and rapidly progressive interstitial lung disease who achieved remission by adding tofacitinib to existing immunosuppressive drugs and present a literature review. While both patients received various immunosuppressive or anti-inflammatory treatments for induction therapy, remission could not be achieved. Subsequently, tofacitinib was administered to reduce the Krebs von den Lungen-6 level 5 months after diagnosis in one patient; the other patient received tofacitinib 4 months after diagnosis to reduce ferritin levels and skin manifestations. Subsequently, bo...
Source: Herpes - April 1, 2024 Category: Infectious Diseases Authors: Susumu Yamazaki Masaki Shimizu Ayane Yakabe Eisuke Inage Keisuke Jimbo Mitsuyoshi Suzuki Futaba Miyaoka Shuya Kaneko Hitoshi Irabu Asami Shimbo Yoshiyuki Ohtomo Masaaki Mori Tomohiro Morio Toshiaki Shimizu Source Type: research
[18F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung Diseases
Conclusion: Previous work has used [18F]FDG uptake in PET/CT as a biomarker in fILD. Here, we highlight a correlation between angiogenesis and [18F]FDG TBR. We show that MVD is higher for UIP than for non-UIP and is associated with mortality in patients with fILD. These data set the scene to investigate the potential role of vasculature and angiogenesis in fibrosis. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - April 1, 2024 Category: Nuclear Medicine Authors: Porter, J. C., Ganeshan, B., Win, T., Fraioli, F., Khan, S., Rodriguez-Justo, M., Endozo, R., Shortman, R. I., Hoy, L. R., Maher, T. M., Groves, A. M. Tags: Clinical Investigations Source Type: research
Analysing the Utility of Single Lung Transplantation in Interstitial Lung Disease Using Discrete Event Simulation of Donor Organ Allocation
This study aimed to model potential UK allocation policies with and without prioritising SLT for ILD using a discrete event simulation engine to compare impacts of this approach. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , W.E. Scott, L. Freitas, R. Hogg, R. Johnson, J. Parmar, A. Fisher Source Type: research
Lung Transplantation for Short-Telomere Interstitial Lung Disease: Outcomes from an Australian Cohort
Purpose: Outcomes after lung transplantation in patients with short-telomere interstitial lung disease (ILD) are presently conflicting. While some studies have suggested an association with clinically significant cytopenia post transplantation and reduced CLAD-free survival, others have suggested outcomes comparable to recipients with interstitial lung disease and normal telomere length. We therefore sought to characterize the demographics and outcomes of an Australian cohort of patients with short telomeres undergoing lung transplantation for fibrosing lung disease. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: L. Zhang, V.P. Lutzky, S.H. Apte, P.L. Groves, M.E. Tan, S. Watson, P. Hopkins, , J. Mackintosh Source Type: research
Paediatric Lung Transplantation for Childhood Interstitial Lung Disease Shows Favorable Outcome Compared with LuTx for Cystic Fibrosis or Pulmonary Hypertension
Purpose: Childhood interstitial lung disease (ChILD) is an umbrella term for more than 200 different rare diseases with a significant morbidity and mortality. Lung transplantation (LuTx) is an established treatment option for ChILD in patients with endstage lung disease. There is limited data on the indications and outcomes following LuTx in ChILD. The aim of this study is to evaluate the long term outcome in ChILD-patients following LuTx and its possible interrelation with the type and severity of the underlying disease. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , F. L änger, F. Ius, C. Müller, K. Schütz, D. Bobylev, J. Salman, N. Schwerk, J. Carlens Source Type: research
ILD Strikes Back: Recurrence of Scleroderma-Related ILD After Lung Transplant
We describe a case of ILD 3 years after a bilateral sequential lung transplant (BSLTx) for Sc-ILD stabilized with tocilizumab. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J. Patil, J. Dunitz, A. Kumar, S. Kiel Source Type: research
Hospital Outcomes Among Patients Admitted with Pulmonary Hypertension Due to Interstitial Lung Diseases
In this study, we examined national trends in ILD related PAH hospitalizations and associated hospital outcomes and their predictors using a national database. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Rubens, M. Roy, A. Saxena, G. Vaidean, J. Jimenez Source Type: research
The Effect of Antifibrotics on the Progression of Pulmonary Hypertension in Patients with Interstitial Lung Disease Listed for Lung Transplantation
Purpose: The antifibrotics (AF) nintedanib and pirfenidone are known to attenuate the progression of fibrotic interstitial lung disease (ILD). It is unknown if these drugs affect the development of pulmonary hypertension (PH) in patients with ILD. We characterized the change in mean pulmonary arterial pressure (mPAP) in patients with ILD who were listed for lung transplantation (LTx) and explored if pre-operative AF therapy was associated with the rate of change of mPAP. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , A. Chandel, M. Zineddin, C. Tang, V. Khangoora, C. King, O. Shlobin, S. Nathan Source Type: research
Serum netrin-1 levels are high in Rheumatoid arthritis associated interstitial lung disease
CONCLUSIONS: Netrin-1 is elevated in the serum of patients with RA-ILD, especially in the UIP pattern. Netrin-1 may be a potential candidate for predicting the development of RA-ILD that should be investigated in the pathophysiological and therapeutic fields.PMID:38556035 | DOI:10.1016/j.clinbiochem.2024.110760 (Source: Clinical Biochemistry)
Source: Clinical Biochemistry - March 31, 2024 Category: Biochemistry Authors: Ahmet Kor Serdar Can G üven Sel çuk Akan Funda Eren Hatice Ecem Konak Y üksel Maraş Kevser Orhan Salim Ne şelioğlu Şükran Erten Source Type: research
Serum netrin-1 levels are high in Rheumatoid arthritis associated interstitial lung disease
CONCLUSIONS: Netrin-1 is elevated in the serum of patients with RA-ILD, especially in the UIP pattern. Netrin-1 may be a potential candidate for predicting the development of RA-ILD that should be investigated in the pathophysiological and therapeutic fields.PMID:38556035 | DOI:10.1016/j.clinbiochem.2024.110760 (Source: Clinical Biochemistry)
Source: Clinical Biochemistry - March 31, 2024 Category: Biochemistry Authors: Ahmet Kor Serdar Can G üven Sel çuk Akan Funda Eren Hatice Ecem Konak Y üksel Maraş Kevser Orhan Salim Ne şelioğlu Şükran Erten Source Type: research
Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease
AbstractAnti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis (anti-MDA5-DM) is frequently complicated by progressive interstitial lung disease (ILD), the prognosis of which is poor, and management is a major challenge. We treated three patients with anti-MDA5-DM-associated ILD (anti-MDA5-DM-ILD) using the Janus kinase (JAK) inhibitor, baricitinib, which improved lung opacities and saved two patients. We reviewed 6 patients with anti-MDA5-DM-ILD who had been treated with tofacitinib at our institution. Five of the patients survived, although discontinuation of tofacitinib due to complications...
Source: Rheumatology International - March 30, 2024 Category: Rheumatology Source Type: research
